

A systematic review of loss of independence in Parkinson's disease

Angus D Macleod^{1*}, Grieve JWK², Carl E Counsell¹

¹Institute of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK

²Institute of Neurological Sciences, Southern General Hospital, 1345 Govan Road, Glasgow, G51 4TF, UK

*Corresponding author: Dr Angus D Macleod

Address: Room 1:014, Institute of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK

Telephone: +44 (0)1224 437120

Fax: +44 (0)1224 551188

E-mail address: Angus.Macleod@abdn.ac.uk

Supplementary table: Dependency and death over time.

Results of included studies	Year of follow-up											
	Baseline	2	3	4	5	6	8	10	12	15	17	20
<i>Inception cohorts</i>												
Hoehn 1967[1]	N indep (%)		79 (72)				16 (39)		8 (17)		2 (11)	
Def: H&Y ≥ 4	N dep (%)		16 (15)				13 (32)		12 (25)		4 (21)	
BL: Recruitment [<2 y from onset]	N dead (%)		15 (14)				12 (30)		28 (58)		13 (68)	
Hoehn 1985[2]	N indep (%)		20 (91)				47 (78)		40 (49)			
Def: H&Y ≥ 4	N dep (%)		2 (9)				7 (12)		17 (21)			
BL: Recruitment [<2 y from onset]	N dead (%)		0 (0)				6 (10)		24 (30)			
Hely 2008[3]	N indep (%)	136 (100)	108 (92)		83 (78)	66 (60)	49 (45)	34 (29)		4 (3)		3 (2)
Def: based on interview	N dep (%)	0 (0)	7 (6)		13 (12)	22 (20)	21 (19)	33 (28)		48 (37)		27 (21)
BL: Recruitment [early disease]	N dead (%)	0 (0)	3 (3)		11 (10)	22 (20)	38 (35)	50 (43)		77 (60)		100 (77)
Auyeung 2012[4]	N indep (%)								54 (32)			
Def: S&E <80%	N dep (%)								117 (68)			
BL: Recruitment	N dead (%)								NS			
Auyeung 2012[4]	N indep (%)	171							110 (64)			
Def: H&Y ≥ 4	N dep (%)	0							61 (36)			
BL: Recruitment	N dead (%)	0							NA			
Velseboer 2013[5]	N indep (%)	129 (100)	113 (93)	107 (86)		80 (67)						
Def: H&Y ≥ 4	N dep (%)	0 (0)	3 (2)	11 (9)		14 (12)						
BL: Diagnosis	N dead (%)	0 (0)	6 (5)	6 (5)		25 (21)						
<i>Non-inception cohort</i>												
Yahr 1976[6]	N dead or dep (%)						NS (48)		NS (60)		NS (63)	
Def: H&Y ≥ 4; BL: Onset ^a												
Aimard 1984[7]	N indep (%)		142 (83)			61 (77)		21 (72)		18 (78)		
Def: H&Y ≥ 4	N dep (%)		29 (17)			18 (23)		8 (28)		5 (22)		
BL: Unclear	N dead (%)		NS			NS		NS		NS		
Guillard 1986[8] – group 1 [diagnosis pre-1971]	N indep (%)					NS			NS			
Def: “loss of autonomy”	N dep (%)					NS (54)			NS (80)			
BL: Start of LD treatment	N dead (%)					NS			NS			
Guillard 1986[8] – group 2 [diagnosis 1971 onwards]	N indep (%)					NS			NS			
Def: “loss of autonomy”	N dep (%)					NS (33)			NS (61)			
BL: Start of LD treatment	N dead (%)					NS			NS			
Chia 1992[9]	N indep (%)	204 (95)				109 (51)						
Def: H&Y ≥ 4	N dep (%)	11 (5)				60 (28)						
BL: Onset	N dead (%)	0 (0)				46 (21)						
Uitti 1993[10]	N indep (%)							63 (36)				
Def: H&Y ≥ 4	N dep (%)							111 (64)				
BL: Recruitment	N dead (%)							NS				
Scigliano 1996[11]	N indep (%)				68 (44)							
Def: Not “able to perform most normal self-care activities”	N dep (%)				87 (56)							
BL: Recruitment	N dead (%)				NS							
Sato 2006[12]	N indep (%)					NS			NS		NS	
Def: H&Y ≥ 4	N dep (%)					NS (7)			NS (28)		NS (41)	
BL: Onset	N dead (%)					NS			NS		NS	
Jasinska-Myga 2012[13]	N indep (%)	491	352		244		143	78	31			
Def: Based on interview	N dep (%)	0	NS (7)		NS (16)		NS (27)	NS (39)	NS (56)			
BL: Recruitment	N dead (%)	0	NS		NS		NS	NS	NS			

^aEach time period 5 years after treatment start of treatment; patients who died before being treated with levodopa not included. Abbreviations: BL: baseline for FU time measurement; Def = definition of dependence; dep = dependence; H&Y = Hoehn & Yahr stage; indep = independence; LD = levodopa; N = number; NS = not stated; y = years.

References

- [1] Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. *Neurology*. 1967;17:427-42.
- [2] Hoehn MM. Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease. *Acta Neurol Scand*. 1985;71:97-106.
- [3] Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. *Mov Disord*. 2008;23:837-44.
- [4] Auyeung M, Tsoi TH, Mok V, Cheung CM, Lee CN, Li R, et al. Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson's disease patients. *J Neurol Neurosurg Psychiatry*. 2012;83:607-11.
- [5] Velseboer DC, Broeders M, Post B, van Geloven N, Speelman JD, Schmand B, et al. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. *Neurology*. 2013;80:627-33.
- [6] Yahr MD. Evaluation of long-term therapy in Parkinson's disease: mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O, eds. *Advances in Parkinsonism*. Basle: Editiones Roche; 1976:435-43.
- [7] Aimard G, Henry E, Devic M. Parkinson's disease. Retrospective study of 302 clinical case records. *Presse Med*. 1984;13:919-22.
- [8] Guillard A, Chastang C, Fenelon G. Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications. *Rev Neurol (Paris)*. 1986;142:207-14.
- [9] Chia LG, Liu LH. Parkinson's disease in Taiwan: an analysis of 215 patients. *Neuroepidemiology*. 1992;11:113-20.
- [10] Uitti RJ, Ahlskog JE, Maraganore DM, Muenter MD, Atkinson EJ, Cha RH, et al. Levodopa Therapy and Survival in Idiopathic Parkinsons-Disease - Olmsted County Project. *Neurology*. 1993;43:1918-26.
- [11] Scigliano G, Musicco M, Soliveri P, Girotti F, Giovannini P, Fetoni V, et al. Progression and prognosis in Parkinson's disease in relation to concomitant cerebral or peripheral vasculopathy. *Adv Neurol*. 1996;69:305-9.
- [12] Sato K, Hatano T, Yamashiro K, Kagohashi M, Nishioka K, Izawa N, et al. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. *Mov Disord*. 2006;21:1384-95.
- [13] Jasinska-Myga B, Heckman MG, Wider C, Putzke JD, Wszolek ZK, Uitti RJ. Loss of ability to work and ability to live independently in Parkinson's disease. *Parkinsonism Relat Disord*. 2012;18(2):130-5.